All In Biotech

Drug Trial Radar · NCT04901195

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

658

Actual

Start

May 27, 2021

Primary completion

Jul 22, 2026

Study completion Jul 22, 2026

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
May 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Conditions

  • Hidradenitis Suppurativa

Interventions

  • BimekizumabDrug

    Subjects will receive bimekizumab at pre-specified time-points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with treatment-emergent adverse events (TEAEs) during the studyTime frame: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)

Locations

145 sites in 19 countries. Site status is shown where the registry gives one.

  • Hs0005 50140

    Birmingham, Alabama

  • Hs0005 50175

    Phoenix, Arizona

  • Hs0005 50162

    Fountain Valley, California

  • Hs0005 50161

    Los Angeles, California

  • Hs0005 50220

    San Diego, California

  • Hs0005 50196

    Thousand Oaks, California

  • Hs0005 50199

    Miami, Florida

  • Hs0005 50205

    North Miami Beach, Florida

  • Hs0005 50152

    Orange Park, Florida

  • Hs0005 50184

    Pembroke Pines, Florida

  • Hs0005 50193

    Sandy Springs, Georgia

  • Hs0005 50280

    Watkinsville, Georgia

  • Hs0005 50234

    Plainfield, Indiana

  • Hs0005 50425

    Murray, Kentucky

  • Hs0005 50198

    Beverly, Massachusetts

  • Hs0005 50146

    Boston, Massachusetts

  • Hs0005 50178

    Clarkston, Michigan

  • Hs0005 50105

    St Louis, Missouri

  • Hs0005 50194

    Omaha, Nebraska

  • Hs0005 50208

    Las Vegas, Nevada

  • Hs0005 50159

    Newington, New Hampshire

  • Hs0005 50137

    East Windsor, New Jersey

  • Hs0005 50200

    Verona, New Jersey

  • Hs0005 50237

    Albuquerque, New Mexico

  • Hs0005 50235

    New York, New York

  • Hs0005 50151

    Chapel Hill, North Carolina

  • Hs0005 50211

    Durham, North Carolina

  • Hs0005 50179

    Winston-Salem, North Carolina

  • Hs0005 50177

    Cincinnati, Ohio

  • Hs0005 50138

    Columbus, Ohio

  • Hs0005 50145

    Columbus, Ohio

  • Hs0005 50202

    Fairborn, Ohio

  • Hs0005 50204

    Tulsa, Oklahoma

  • Hs0005 50147

    Hershey, Pennsylvania

  • Hs0005 50008

    Johnston, Rhode Island

  • Hs0005 50180

    Providence, Rhode Island

  • Hs0005 50084

    Charleston, South Carolina

  • Hs0005 50236

    Greenville, South Carolina

  • Hs0005 50142

    Nashville, Tennessee

  • Hs0005 50201

    Arlington, Texas

Showing 40 of 145 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.